SCHEMBL6264530

SCHEMBL6264530

COc1cc(OC)cc(N2CCN(C(=O)c3cc(N4CCCCC4)nn3-c3ccccc3)CC2)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
MAPT P10636 4/20 0.47
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 4/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HTT P42858 2/20 0.46
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HPGD P15428 2/20 0.44
MAPK1 P28482 1/20 0.44
LMNA P02545 2/20 0.44
TSHR P16473 2/20 0.44
MEN1 O00255 1/20 0.44
CNR1 P21554 1/20 0.44
GAA P10253 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6263546 0.99 KMT2A (0.56) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL6261059 0.97 KMT2A (0.56) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL6260174 0.90 RAB9A (0.57) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL6263525 0.85 KMT2A (0.53) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL6265709 0.85 KMT2A (0.59) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL6263564 0.84 KMT2A (0.55) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL6260121 0.84 KMT2A (0.55) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL6264062 0.83 KMT2A (0.53) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL6264113 0.83 ALDH1A1 (0.55) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL6413083 0.83 KMT2A (0.50) KMT2AMAPTALDH1A1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590329-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2005-11-02 EP disclosed
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-06-16 US disclosed
WO-2004078732-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AHR, NQO1, ARNT KMT2A 1284/4885MAPT 4098/4885ALDH1A1 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.